Massachusetts Financial Trims Stake in Johnson & Johnson

Major investor reduces holdings in pharmaceutical giant by 6.7%

Apr. 14, 2026 at 2:55pm

Got story updates? Submit your updates here. ›

An extreme close-up of various gears, levers, and components that make up the internal financial mechanisms of a large pharmaceutical corporation, conveying a sense of the complex operations behind the scenes.A close-up look at the complex financial machinery powering a major pharmaceutical company like Johnson & Johnson.New Brunswick Today

Massachusetts Financial Services Co. MA, a prominent institutional investor, has reduced its stake in Johnson & Johnson (NYSE: JNJ) by 6.7% during the fourth quarter of 2025, according to a recent 13F filing with the SEC. The firm now owns approximately 16.4 million shares of the pharmaceutical company, valued at $3.39 billion.

Why it matters

This reduction in holdings by a major institutional investor highlights the shifting dynamics in the healthcare and pharmaceutical sectors, as investors weigh factors like growth prospects, valuation, and market conditions when allocating capital. Johnson & Johnson's performance and outlook will continue to be closely watched by the investment community.

The details

According to the 13F filing, Massachusetts Financial Services Co. MA sold 1,172,786 shares of Johnson & Johnson during the fourth quarter. The firm now owns around 0.68% of the company's outstanding shares. Johnson & Johnson remains the 7th largest holding in Massachusetts Financial Services' investment portfolio.

  • The stake reduction occurred during the fourth quarter of 2025.
  • Massachusetts Financial Services Co. MA filed the 13F report disclosing the changes on April 14, 2026.

The players

Massachusetts Financial Services Co. MA

A major institutional investment management firm that oversees a diversified portfolio of equity and fixed-income assets.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Johnson & Johnson's upcoming Q1 earnings report and guidance for any signs of changing market dynamics or shifts in the company's business performance.

The takeaway

This reduction in holdings by a prominent institutional investor like Massachusetts Financial Services highlights the ongoing shifts and uncertainties in the healthcare and pharmaceutical sectors, as investors carefully evaluate factors like growth, valuation, and market conditions when making portfolio decisions.